- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- May 2025
- 134 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- June 2025
- 83 Pages
United States
From €5211EUR$5,950USD£4,523GBP
- Report
- July 2025
- 155 Pages
North America
From €3022EUR$3,450USD£2,623GBP
- Report
- March 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2409EUR$2,750USD£2,090GBP
- Report
- May 2024
- 185 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- August 2022
- 115 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- May 2024
- 137 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$4,281USD£3,144GBP
Vedolizumab is a biologic drug used to treat gastrointestinal diseases such as ulcerative colitis and Crohn's disease. It is a monoclonal antibody that binds to the α4β7 integrin, a protein found on the surface of certain white blood cells. This binding prevents the white blood cells from entering the gastrointestinal tract, reducing inflammation and symptoms of the disease. Vedolizumab is administered intravenously and is typically used in combination with other medications.
Vedolizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2014. It is one of several biologic drugs used to treat gastrointestinal diseases, and is often used when other treatments have failed.
Companies in the Vedolizumab market include Takeda Pharmaceuticals, AbbVie, and UCB. Show Less Read more
